CASPOFUNGIN ACETATE

Peak

caspofungin acetate

NDAINTRAVENOUSPOWDER
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4

Mechanism of Action

[see Microbiology ()].

Clinical Trials (4)

NCT00635648Phase 3Completed

A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)

Started Jan 2008
63 enrolled
Fungal Infection
NCT00548080Phase 3Completed

Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)

Started Mar 2006
131 enrolled
Fungal Infection
NCT00292071Phase 2Completed

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Started May 2004
16 enrolled
Fungal Infection
NCT00238355Phase 2Terminated

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Started Aug 2003
13 enrolled
InfectionUnspecified Adult Solid Tumor, Protocol Specific

Loss of Exclusivity

LOE Date
Dec 21, 2032
82 months away
Patent Expiry
Dec 21, 2032

Patent Records (1)

Patent #ExpiryTypeUse Code
9636407
Dec 21, 2032
Product